Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | President & CEO | February 26, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAINSTORM CELL THERAPEUTICS INC.
Report date February 26, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,000,960 |
Reported balance
After 2026-02-26 transaction · row 1
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 1,800,000 · Balance 2,000,960 F1: Represents shares of restricted stock units ("RSUs") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of restricted stock units ("RSUs") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed May 29, 2026 21:02 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 1,800,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-068339 · tm2615354-5_4seq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,960 F1 · shares: Represents shares of restricted stock units ("RSUs") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 22:36 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000895 · tm251864-10_4seq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,960 F1 · shares: Represents shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 12:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 1,836 | $3.43 | $6,292.34 |
DisclosureSEC source: 0001104659-24-105215 · tm2425378-1_4seq1.xml · nonDerivative · entry 2 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,960 F2 · shares: Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. F2 · price: Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $3.40 to $3.45, inclusive. F2 · balance_after: Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 12:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 22,000 | $0.23 | $5,016.00 |
DisclosureSEC source: 0001104659-24-105215 · tm2425378-1_4seq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,186,865 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.2258 to $0.2302, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4. Read SEC document |
| May 28, 2024 Filed Jun 3, 2024 13:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 15,000 | $0.52 | $7,774.50 |
DisclosureSEC source: 0001104659-24-067529 · tm2416255-1_4seq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,164,865 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.5161 to $0.5194, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| May 28, 2024 Filed Jul 31, 2024 20:09 UTC Amendment | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 15,000 | $0.52 | $7,774.50 |
DisclosureSEC source: 0001104659-24-084344 · tm2420560-7_4aseq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,164,865 F1 · kind: On June 3, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. F2 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.5161 to $0.5194, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 22, 2024 Filed May 23, 2024 10:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 25,000 | $0.64 | $16,000.00 |
DisclosureSEC source: 0001104659-24-064415 · tm2415334-1_4seq1.xml · nonDerivative · entry 2 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,149,865 Read SEC document |
| May 22, 2024 Filed Jul 31, 2024 20:08 UTC Amendment | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 25,000 | $0.64 | $16,000.00 |
DisclosureSEC source: 0001104659-24-084343 · tm2420560-6_4aseq1.xml · nonDerivative · entry 2 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,149,865 F1 · kind: On May 23, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. Read SEC document |
| May 21, 2024 Filed May 23, 2024 10:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 25,000 | $0.58 | $14,475.00 |
DisclosureSEC source: 0001104659-24-064415 · tm2415334-1_4seq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,124,865 Read SEC document |
| May 21, 2024 Filed Jul 31, 2024 20:08 UTC Amendment | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 25,000 | $0.58 | $14,475.00 |
DisclosureSEC source: 0001104659-24-084343 · tm2420560-6_4aseq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,124,865 F1 · kind: On May 23, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. Read SEC document |
| May 13, 2024 Filed May 14, 2024 11:53 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 10,000 | $0.49 | $4,900.00 |
DisclosureSEC source: 0001104659-24-060889 · tm2414376-1_4seq1.xml · nonDerivative · entry 3 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,099,865 Read SEC document |
| May 13, 2024 Filed Jul 31, 2024 20:07 UTC Amendment | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 10,000 | $0.49 | $4,900.00 |
DisclosureSEC source: 0001104659-24-084341 · tm2420560-5_4aseq1.xml · nonDerivative · entry 3 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,099,865 F1 · kind: On May 14, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. Read SEC document |
| May 11, 2024 Filed May 14, 2024 11:53 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 10,000 | $0.47 | $4,665.00 |
DisclosureSEC source: 0001104659-24-060889 · tm2414376-1_4seq1.xml · nonDerivative · entry 2 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,089,865 Read SEC document |
| May 11, 2024 Filed Jul 31, 2024 20:07 UTC Amendment | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 10,000 | $0.47 | $4,665.00 |
DisclosureSEC source: 0001104659-24-084341 · tm2420560-5_4aseq1.xml · nonDerivative · entry 2 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,089,865 F1 · kind: On May 14, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. Read SEC document |
| May 10, 2024 Filed May 14, 2024 11:53 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 20,000 | $0.47 | $9,300.00 |
DisclosureSEC source: 0001104659-24-060889 · tm2414376-1_4seq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,079,865 Read SEC document |
| May 10, 2024 Filed Jul 31, 2024 20:07 UTC Amendment | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 20,000 | $0.47 | $9,300.00 |
DisclosureSEC source: 0001104659-24-084341 · tm2420560-5_4aseq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,079,865 F1 · kind: On May 14, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. Read SEC document |
| May 07, 2024 Filed May 7, 2024 23:41 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 66,300 | $0.37 | $24,816.09 |
DisclosureSEC source: 0001104659-24-058218 · tm2413818-1_4seq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,059,865 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.3738 to $0.3747, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| May 07, 2024 Filed Jul 31, 2024 20:07 UTC Amendment | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 66,300 | $0.37 | $24,816.09 |
DisclosureSEC source: 0001104659-24-084339 · tm2420560-4_4aseq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,059,865 F1 · kind: On May 7, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. F2 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.3738 to $0.3747, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 06, 2024 Filed May 7, 2024 13:14 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 135,000 | $0.38 | $50,665.50 |
DisclosureSEC source: 0001104659-24-057784 · tm2413699-1_4seq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 993,565 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.3498 to $0.399, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| May 06, 2024 Filed Jul 31, 2024 20:06 UTC Amendment | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 135,000 | $0.38 | $50,665.50 |
DisclosureSEC source: 0001104659-24-084337 · tm2420560-3_4aseq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 993,565 F1 · kind: On May 7, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. F2 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.3498 to $0.399, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| April 19, 2024 Filed Apr 25, 2024 20:01 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 15,000 | $0.52 | $7,798.50 |
DisclosureSEC source: 0001104659-24-051948 · tm2412707d1_4seq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 858,565 Read SEC document |
| April 19, 2024 Filed Jul 31, 2024 20:06 UTC Amendment | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 15,000 | $0.52 | $7,798.50 |
DisclosureSEC source: 0001104659-24-084336 · tm2420560-2_4aseq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 858,565 F1 · kind: On April 25, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. Read SEC document |
| April 18, 2024 Filed Apr 19, 2024 10:05 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 115,072 | $0.53 | $60,470.34 |
DisclosureSEC source: 0001104659-24-049027 · tm2412256-1_4seq1.xml · nonDerivative · entry 2 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 843,565 F2 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.4936 to $0.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| April 18, 2024 Filed Jul 31, 2024 20:05 UTC Amendment | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 115,072 | $0.53 | $60,470.34 |
DisclosureSEC source: 0001104659-24-084334 · tm2420560-1_4aseq1.xml · nonDerivative · entry 2 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 843,565 F1 · kind: On April 19, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. F3 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.4936 to $0.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 10:05 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 130,000 | $0.55 | $70,941.00 |
DisclosureSEC source: 0001104659-24-049027 · tm2412256-1_4seq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 728,493 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.5392 to $0.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| April 17, 2024 Filed Jul 31, 2024 20:05 UTC Amendment | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 130,000 | $0.55 | $70,941.00 |
DisclosureSEC source: 0001104659-24-084334 · tm2420560-1_4aseq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 728,493 F1 · kind: On April 19, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. F2 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.5392 to $0.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| March 11, 2024 Filed Mar 14, 2024 00:54 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 305,198 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-034091 · tm248822-1_4seq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 598,493 F1 · shares: The grant of restricted stock awards ("RSAs") to the Reporting Person as reported herein was approved by the board of directors of the Issuer on March 11, 2024 ("Grant Date") as part of the Issuer's grant of equity awards in the ordinary course. The RSAs shall vest in equal yearly installments over the course of two (2) years, with vesting occurring on each of the first and second anniversary of the Grant Date. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 20:05 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 31,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-087819 · tm2322868-2_4seq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,295 F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of July 26, 2023, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. Read SEC document |
| April 20, 2023 Filed Apr 24, 2023 10:44 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-048639 · tm2313513-2_4seq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · President & Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,110 F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares were fully vested upon grant. Read SEC document |
| September 18, 2022 Filed Jan 4, 2023 12:35 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 31,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-000634 · tm231419-2_4seq1.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,110 F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of July 26, 2022, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. Read SEC document |
| December 10, 2021 Filed Dec 11, 2021 01:04 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 31,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-148753 · tm2135032-8_4.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,925 F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of July 26, 2021, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. Read SEC document |
| July 26, 2020 Filed Jul 31, 2020 21:10 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 31,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-089158 · tm2025773d1_4.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,740 F1 · shares: Shares acquired are shares of restricted stock awarded on July 26, 2020 under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. Read SEC document |
| July 26, 2019 Filed Jul 26, 2019 21:03 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 31,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-036266 · tv525662_4.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,166,155 F1 · shares: Shares acquired are shares of restricted stock awarded on July 26, 2019 under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. F2 · balance_after: Includes (i) 1,933,794 shares of Common Stock owned by ACCBT Corp. and (ii) 138,806 shares of Common Stock owned by ACC International Holdings Ltd. Reporting Person may be deemed the beneficial owner of these shares. Read SEC document |
| July 26, 2018 Filed Jul 27, 2018 20:05 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 31,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-040473 · tv498316_4.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,134,970 F1 · shares: Shares acquired are shares of restricted stock awarded on July 26, 2018 under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. F2 · balance_after: Includes (i) 1,933,794 shares of Common Stock owned by ACCBT Corp. and (ii) 138,806 shares of Common Stock owned by ACC International Holdings Ltd. Reporting Person may be deemed the beneficial owner of these shares. Read SEC document |
| July 26, 2017 Filed Jul 26, 2017 21:29 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (right to buy) · Derivative | 41,580 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001144204-17-038410 · v471333_4.xml · derivative · entry 2 Lebovits Chaim · CIK 0001406302 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,580 Underlying: Common Stock · 41,580 shares Expires 2019-07-26 F3 · derivative.exercise_date: Option is fully vested exercisable as of the date of grant and shall remain exercisable until the 2nd anniversary of the date of grant. Read SEC document |
| July 26, 2017 Filed Jul 26, 2017 21:29 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 31,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-038410 · v471333_4.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,103,785 F1 · shares: Shares acquired are shares of restricted stock awarded on July 26, 2017 under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. F2 · balance_after: Includes (i) 1,933,794 shares of Common Stock owned by ACCBT Corp. and (ii) 138,806 shares of Common Stock owned by ACC International Holdings Ltd. Reporting Person may be deemed the beneficial owner of these shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.